Thyrocare Technologies Ltd · NSE:THYROCARE
Thyrocare Technologies — Q4 FY2018 Earnings Presentation
23 slides from Thyrocare Technologies's earnings presentation, May 3, 2018
Slide 1: Thyrocare - Presentation on Annual Results
Thyrocare® Think Thyroid. Think Thyrocare. May 03, 2018 The National Stock Exchange of India Limited The Bombay Stock Exchange Ltd Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 Dear Sirs, Sub: Presentation on Annual Results f
Slide 2: Thyrocare Technologies Limited Q4-FY18 / FY18 Presentation
Thyrocare Technologies Limited Q4-FY18 / FY18 Presentation
Slide 3: Disclaimer
Disclaimer • This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, informat
Slide 4: FY18A and Q4-FY18 Highlights
FY18A and Q4-FY18 Highlights
Slide 5: Key Highlights – FY2018
Slide # 4 Key Highlights* – FY2018 • FY18A Highlights: • FY2018 Consolidated Profit Before Exceptional Items & Tax Of ₹ 1,472 Million, ▲ 35% • FY2018 Consolidated EBITDA Of ₹ 1,443 Million, ▲ 26% • FY2018 Consolidated Revenues Of ₹ 3,563 Million, ▲ 17% • Q4-FY18A Highlights: • Quarterly Consolidated
Slide 6: Pathology – Attractive CAGRs on all metrics
Slide # 5 Pathology – Attractive CAGRS on all metrics Pathology Revenues (INR mn) Number of Samples (mn) 3 Year CAGR 22% 3 Year CAGR 16.3 23% 14.2 11.6 3,318 9.1 7.0 2,860 2,254 FY14 FY15 FY16 FY17 FY18 1,778 1,500 Number of Investigations (mn) 3 Year CAGR 29% 171.0 142.0 104.1 80.1 58.3 FY14 FY15 F
Slide 7: Imaging has consistently grown; 30%+ in FY18A
Slide # 6 Imaging has consistently grown; 30%+ in FY18A Imaging Revenues (INR mn) Number of Scans 3 Year CAGR 28% 3 Year CAGR 27% 23,419 245 18,610 184 15,896 156 11,173 119 23 2,361 FY14 FY15 FY16 FY17 FY18 FY14 FY15 FY16 FY17 FY18
Slide 8: Group CAGR – 25% over 3 years
Slide # 7 Group CAGR – 25% over 3 years Consolidated Group Revenues (INR mn) 3 Year CAGR 25% 3,563 3,044 2,410 1,830 FY15 FY16 FY17 FY18
Slide 9: Transition to IndAS (Indian Accounting Standards)
Transition to IndAS (Indian Accounting Standards) Key IndAS Adjustments: [Rs. in million] Year ended 31 March 2017 Qtr ended 31 March 2017 • Re-imbursement of advertisement expenses by shareholders – Non reciprocal contributions received from the shareholders are considered as capital contribution a
Slide 10: Consolidated Financials
Consolidated Financials Thyrocare’ ‘Think Thyroid. Think Thyrocare
Slide 11: Consolidated Financials
Consolidated Financials Thyrocare Technologies Limited [Consolidated] Thyrocare Technologies Limited [Consolidated] P&L Statement (INR mn, except per share data) Balance Sheet (INR mn) Particulars Financial Year Ending YoY Growth 3 months ended YoY Growth Particulars 31 Mar 18 31 Mar 17 31 Mar 18 31
Slide 12: Thyrocare Standalone
Thyrocare Standalone Thyrocare’ ‘Think Thyroid. Think Thyrocare
Slide 13: Standalone Financials
Standalone Financials Thyrocare Technologies Limited Thyrocare Technologies Limited [Diagnostic business] (Rs. in million, except per share data) Balance sheet data Particulars Financial Year Ending YoY Growth 3 months ended YoY Growth Particulars 31 Mar 18 31 Mar 17 31 Mar 18 31 Mar 17 31 Mar 18 31
Slide 14: Key Financial Trends - Thyrocare
Key Financial Trends - Thyrocare Revenue (INR mn) EBITDA (INR mn) 357.6 352.9 900.3 338.8 336.7 821.4 817.9 823.6 311.5 778.4 298.7 734.0 261.3 259.7 645.1 656.9 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY17 FY18 FY17 FY18 EBITDA Margin(%) 44% 43% 41% 41% 41% 40% 39% 38% Q1 - FY17 Q2 - FY17 Q3 - FY17 Q4 - FY17 Q1 -
Slide 15: Key Operating Metrics – Business Lines
Key Operating Metrics – Business Lines Revenue Breakup (INR mn) Volume Breakup (‘000 Samples) Q4-FY18 158 252 15 409 Q4-FY18 124.8 392.1 231.3 3,606.9 Q3-FY18 129 210 14 370 Q3-FY18 99.9 328.0 185.9 3,259.4 Q2-FY18 167 238 17 341 Q2-FY18 126.2 374.4 219.5 3,362.3 Q1-FY18 188 227 19 328 Q1-FY18 146.9
Slide 16: Key Operating Metrics – Regional Breakup
Key Operating Metrics – Regional Breakup Value Breakup (INR mn) Volume Breakup (mn Samples) Q4-FY18 134 201 277 142 44 Q4-FY18 0.9 1.3 1.0 1.0 0.1 Q3-FY18 131 183 266 125 19 Q3-FY18 0.7 1.2 0.8 0.9 0.2 Q2-FY18 226 197 205 132 3 Q2-FY18 1.0 1.2 0.9 0.9 0.0 Q1-FY18 206 199 221 132 4 Q1-FY18 1.0 1.2 0.
Slide 17: Operating Data
Operating Data Thyrocare Technologies Limited (Rs. in million, except per share data) Particulars Financial Year Ending YoY Growth 3 months ended YoY Growth 31 Mar 18 31 Mar 17 31 Mar 18 31 Mar 17 B2B revenue (in million) 2,375.54 2,005.61 18% 660.68 555.20 19% B2C revenue (in million) 707.28 626.65
Slide 18: Nueclear Standalone
Nueclear Standalone Nue@clear
Slide 19: Standalone Financials - Nueclear
Standalone Financials - Nueclear Nueclear Healthcare Limited Nueclear Healthcare Limited [Radiology business] (Rs. in million, except per share data) (Rs. in million, except per share data) Balance sheet data Particulars Financial Year Ending YoY Growth 3 months ended YoY Growth Particulars 31 Mar 1
Slide 20: Key Financial Trends - Nueclear
Key Financial Trends - Nueclear Revenue (INR mn) EBITDA (INR mn) 66.2 62.5 60.3 15.6 15.4 56.2 14.0 47.4 46.8 47.6 42.3 4.3 4.0 1.8 1.8 0.3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY17 FY18 FY17 FY18 EBITDA Margin 25% 24% 24% 10% 7% 4% 4% 1% Q1-FY17 Q2-FY17 Q3-FY17 Q4-FY17 Q1-FY18 Q2-FY18 Q3-FY18 Q4-FY18
Slide 21: Centerwise Scan Volumes
Centerwise Scan Volumes Centerwise Scan Volumes 18 100% 49 158 320 199 304 94 356 292 529 580 440 90% 471 436 213 611 224 579 689 548 80% 659 683 725 70% 738 808 847 2,101 2,339 60% 1,972 1,766 2,090 50% 1,839 1,646 1,643 40% 30% 20% 1,731 1,889 1,717 1,741 1,967 1,837 1,750 1,840 10% 0% Q1-FY17 Q2-
Slide 22: Centerwise Scan Revenues
Centerwise Scan Revenues Centerwise Scan Revenues (INR mn) 0.2 100% 0.8 1.0 2.8 3.2 4.8 2.8 5.2 4.8 90% 5.7 5.6 3.2 1.0 3.4 7.0 3.2 2.7 5.7 8.2 80% 6.6 6.4 7.1 8.2 70% 7.6 8.3 17.2 19.1 60% 8.3 16.0 14.8 50% 18.4 18.6 16.2 40% 15.2 30% 20% 15.9 17.4 15.6 15.9 18.2 18.3 17.3 16.5 10% 0% Q1-FY17 Q2-FY
Slide 23: Thank You
Thank You O Think Thyroid. Think Thyrocare. Nuclear NATIONWIDE NETWORKED
Thyrocare Technologies — Q4 FY2018 Earnings Presentation on 6ix